罗欣药业(002793) - 2025 Q4 - 年度业绩预告

Financial Projections - The estimated net profit for 2025 is projected to be between -34,000 and -25,000 thousand yuan, compared to -96,549.62 thousand yuan in the same period last year [4]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between -35,000 and -26,000 thousand yuan, compared to -76,812.08 thousand yuan in the same period last year [4]. - The basic earnings per share is expected to be between -0.3300 and -0.2300 yuan, compared to -0.9058 yuan in the same period last year [4]. Business Strategy and Growth - The company continues to strategically focus on the pharmaceutical industry, particularly in the digestive system field, with significant growth driven by the core innovative drug Tegoprazan [6]. - The commercial progress of Tegoprazan has been strong, with new indications added to the medical insurance directory, which is expected to enhance sales scale and operational efficiency [7]. Asset Management and Losses - The negative impact from impairment losses related to long-term assets of subsidiaries has significantly decreased in 2025 compared to 2024 [7]. - The company has initiated disposal procedures for loss-making businesses, which are expected to reduce the impact of losses once completed [8]. - The company has confirmed fair value losses related to financial liabilities from its investment in Shangyao Luoxin, which will be audited for final amounts [7]. Financial Data Caution - The company warns that the financial data presented is preliminary and subject to final audit by the accounting firm [9]. - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the financial estimates [9].